VFA
AMLX icon

Valeo Financial Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Valeo Financial Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$293K Buy
10,074
+29
+0.3% +$769 0.01% 643
2026
Q2 		$180K Buy
10,045
+45
+0.5% +$696 ﹤0.01% 776
2026
Q1 		$139K Sell
10,000
-5,000
-33% -$70.3K ﹤0.01% 707
2025
Q4 		$181K Buy
15,000
+5,000
+50% +$67.9K ﹤0.01% 765
2025
Q3 		$136K Hold
10,000
– – ﹤0.01% 782
2025
Q2 		$64.1K Hold
10,000
– – ﹤0.01% 750
2025
Q1 		$35.4K Buy
+10,000
New +$35.6K ﹤0.01% 678

Other funds holding AMLX

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Valeo Financial Advisors's AMLX Position: Q3 2026 in Review

Valeo Financial Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 0.29% in Q3 2026, buying an estimated $769 and bringing the position to 10,074 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #643.

Valeo Financial Advisors first reported a position in AMLX in Q1 2025 and has held it in 7 quarters since. 6 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Valeo Financial Advisors held 10,074 shares of Amylyx Pharmaceuticals worth $293K as of Q3 2026.
  • Valeo Financial Advisors bought 29 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $769.
  • Amylyx Pharmaceuticals made up 0.01% of Valeo Financial Advisors's portfolio in Q3 2026, its #643 holding.
  • Valeo Financial Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • 6 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Valeo Financial Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.